The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. UroGen Pharma Ltd shares valued at $176,900 were sold by Schoenberg Mark on Aug 11 ’25. At $17.69 per share, Schoenberg Mark sold 10,000 shares. The insider’s holdings dropped to 148,229 shares worth approximately $2.85 million following the completion of this transaction.
Also, Smith Jason Drew sold 7,522 shares, netting a total of over 143,971 in proceeds. Following the sale of shares at $19.14 each, the insider now holds 41,492 shares.
Before that, Schoenberg Mark had sold 5,149 shares from its account. In a trade valued at $98,552, the Chief Medical Officer traded UroGen Pharma Ltd shares for $19.14 each. Upon closing the transaction, the insider’s holdings decreased to 5,149 shares, worth approximately $3.04 million.
As published in their initiating research note from Piper Sandler on August 19, 2025, UroGen Pharma Ltd [URGN] has been an Overweight and the price target has been revised to $36. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid June. As of May 22, 2025, H.C. Wainwright has decreased its “Buy” rating to a “Neutral” for URGN. Earlier on April 16, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for URGN stock.
Analyzing URGN Stock Performance
On last trading session, UroGen Pharma Ltd [NASDAQ: URGN] plunged -1.54% to $19.24. The stock’s lowest price that day was $19.14, but it reached a high of $19.63 in the same session. During the last five days, there has been a drop of approximately -2.73%. Over the course of the year, UroGen Pharma Ltd shares have jumped approximately 34.64%. Shares of the company reached a 52-week high of $21.01 on 08/05/25 and a 52-week low of $3.42 on 05/21/25.
Support And Resistance Levels for UroGen Pharma Ltd (URGN)
According to the 24-hour chart, there is a support level at 19.02, which, if violated, would cause prices to drop to 18.79. In the upper region, resistance lies at 19.55. The next price resistance is at 19.85. RSI (Relative Strength Index) is 55.29 on the 14-day chart, showing neutral technical sentiment.
Is UroGen Pharma Ltd subject to short interest?
Stocks of UroGen Pharma Ltd saw a sharp steep in short interest on 2025-08-15 dropping by -0.42 million shares to 6.87 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 7.29 million shares. A decline of -6.17% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.3 of the overall float, the days-to-cover ratio (short ratio) decline to 5.3.
Which companies own the most shares of UroGen Pharma Ltd (URGN)?
In terms of UroGen Pharma Ltd share price expectations, FactSet research, analysts set an average price target of 23.5 in the next 12 months, up nearly 20.27% from the previous closing price of $19.54. Analysts anticipate UroGen Pharma Ltd stock to reach 31 by 2025, with the lowest price target being 16. In spite of this, 7 analysts ranked UroGen Pharma Ltd stock as Buy at the end of 2025. On February 19, 2025, Ladenburg Thalmann assigned a price target of “a Buy” to the stock and resumed coverage with a $31.
